Diagnosing Nephrogenic Systemic Fibrosis (NSF)
When it comes to diagnosing nephrogenic systemic fibrosis (NSF), there are a few key steps that medical professionals follow. Firstly, they assess visible symptoms exhibited by the patient. This can include changes in the skin, such as thickening, hardening, or discoloration.
In addition to assessing visible symptoms, doctors also conduct a histological examination of skin biopsies. This involves analyzing tissue samples under a microscope to detect any abnormalities or signs of NSF.
Another important aspect of diagnosing NSF is determining the level of exposure to gadolinium-based contrast agents (GBCA). These are substances commonly used in medical imaging procedures. By assessing the degree of GBCA exposure, doctors can better understand the potential link between the use of these agents and the development of NSF.
It’s worth noting that the symptoms of NSF can resemble those of other conditions. Therefore, medical professionals also test for these alternative conditions when making a diagnosis. For instance, individuals with limited exposure to GBCA may instead have a skin disorder like systemic sclerosis, cellulitis, or eosinophilic fasciitis, which can present similar symptoms to NSF.
Who is Most Vulnerable to NSF?
Individuals who undergo regular peritoneal or kidney dialysis are at a greater risk of developing Nephrogenic Systemic Fibrosis (NSF) compared to those who do not require dialysis. Moreover, people who receive Gadolinium-Based Contrast Agents (GBCA) injections following severe kidney injuries caused by accidents may also be susceptible to NSF if they do not receive kidney dialysis prior to the injections. The chances of developing NSF are more likely as kidney function declines, depending on the extent of exposure to GBCA.